• Depot
  • Watchlist
  • Glocke
  • Handeln

    • NeuroSense Therapeutics Ltd News

    1,23 $ -2,38% -0,03 $
    In : 1,1503 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A3DFK1
    ISIN: IL0011809592
    US-Symbol: NRSN
    Typ: Aktie

    NeuroSense Therapeutics Ltd News

    22.04.24 - PR Newswire
    NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
    NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease PR Newswire
    18.04.24 - PR Newswire
    NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
    NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting PR Newswire
    12.04.24 - PR Newswire
    NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
    NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 PR Newswire
    10.04.24 - PR Newswire
    NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
    NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
    09.04.24 - PR Newswire
    NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
    NeuroSense Collaborates with Lonza to Identify Exosome-​based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics PR Newswire
    05.04.24 - PR Newswire
    NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
    NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire
    21.02.24 - PR Newswire
    NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
    NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire
    07.02.24 - PR Newswire
    NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
    NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire
    09.01.24 - PR Newswire
    NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
    NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated ...
    27.12.23 - PR Newswire
    NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
    NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement PR Newswire
    14.12.23 - PR Newswire
    NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
    NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial PR Newswire
    05.12.23 - PR Newswire
    Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?
    Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands? PR Newswire
    05.12.23 - PR Newswire
    NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
    NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints PR Newswire
    04.12.23 - PR Newswire
    NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
    NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023 PR Newswire
    28.11.23 - PR Newswire
    NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
    NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update PR Newswire
    13.11.23 - PR Newswire
    NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
    NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness PR Newswire
    09.11.23 - PR Newswire
    NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
    NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences PR Newswire
    06.11.23 - PR Newswire
    NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
    NeuroSense Completes Dosing of Last Patient in the Double-​Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 PR Newswire
    01.11.23 - PR Newswire
    NeuroSense Therapeutics to Participate in BIO-Europe Fall
    NeuroSense Therapeutics to Participate in BIO-​Europe Fall PR Newswire
    17.10.23 - PR Newswire
    NeuroSense CEO Provides Q3 2023 Update
    NeuroSense CEO Provides Q3 2023 Update PR Newswire

    Newssuche

    Videos

    newspaper
    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »